RCEL in the 13F filings
Avita Therapeutics Inc · CUSIP 05380C102
- Quarter end
- 31 Mar 2021
- the date the book describes
- Filed
- 17 May 2021
- up to 45 days after the quarter end
- Managers listing it
- 1
- at least, of 95 tracked, among listed positions
- Comparable managers
- 92
- filed both Q4 2020 and Q1 2021; 0 listed it in both
- Shares listed
- 800,000
- combined, among listed positions
- Reported value
- $16m
- combined, at the quarter end
Managers listing RCEL in Q1 2021
1 of 1 holder
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Farallon Capital Management LLC | 800,000 | $16m | 0.08% | New | new | 17 May 2021 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Farallon Capital Management LLCnew position · 800,000 shares now+800,000
Reductions
No reduction among listed positions.
New positions and exits
New (1)
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 1 | $2.6m | n.a. | n.a. |
| Q1 2021 | 1 | $16m | n.a. | n.a. |
| Q2 2021 | 1 | $16m | n.a. | n.a. |
| Q3 2021 | 1 | $14m | n.a. | n.a. |
| Q4 2021 | 1 | $9.6m | n.a. | n.a. |
| Q1 2022 | 1 | $6.8m | n.a. | n.a. |
| Q2 2022 | 1 | $2.8m | n.a. | n.a. |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
RCEL and LLY →RCEL and JNJ →RCEL and VRTX →Choose a stock to compare with RCEL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own RCEL, latest filings →Back to the 13F Explorer →